Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
WARNING
METHAMPHETAMINE HAS A HIGH POTENTIAL FOR ABUSE. IT SHOULD THUS BE TRIED ONLY IN WEIGHT REDUCTION PROGRAMS FOR PATIENTS IN WHOM ALTERNATIVE THERAPY HAS BEEN INEFFECTIVE. ADMINISTRATION OF METHAMPHETAMINE FOR PROLONGED PERIODS OF TIME IN OBESITY MAY LEAD TO DRUG DEPENDENCE AND MUST BE AVOIDED. PARTICULAR ATTENTION SHOULD BE PAID TO THE POSSIBILITY OF SUBJECTS OBTAINING METHAMPHETAMINE FOR NON-THERAPEUTIC USE OR DISTRIBUTION TO OTHERS, AND THE DRUG SHOULD BE PRESCRIBED OR DISPENSED SPARINGLY. MISUSE OF METHAMPHETAMINE MAY CAUSE SUDDEN DEATH AND SERIOUS CARDIOVASCULAR ADVERSE EVENTS.
DESOXYN® (methamphetamine hydrochloride tablets, USP), chemically known as (S)-N,α-dimethylbenzeneethanamine hydrochloride, is a member of the amphetamine group of sympathomimetic amines. It has the following structural formula:
 |
DESOXYN tablets contain 5 mg of methamphetamine hydrochloride for oral administration.
Corn starch, lactose, sodium paraminobenzoate, stearic acid and talc.
DESOXYN is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 years of age and older.
Prior to treating patients with DESOXYN, assess:
Administer DESOXYN tablets orally once daily or in two divided doses daily. Avoid taking DESOXYN late in the evening due to the risk of insomnia.
For pediatric patients 6 years of age and older, the recommended starting dosage is 5 mg DESOXYN once or twice daily. The daily dosage may be increased in increments of 5 mg at weekly intervals based on clinical response of the patient. The recommended dosage range is 20 mg to 25 mg daily.
Agents that alter urinary pH can impact excretion and alter blood levels of amphetamine. Acidifying agents (e.g., ascorbic acid) decrease blood levels, while alkalinizing agents (e.g., sodium bicarbonate) increase blood levels. Adjust DESOXYN dosage based on clinical response [see DRUG INTERACTIONS].
Tablets: 5 mg of methamphetamine hydrochloride as a white tablet imprinted with the letters OV on one side and the number 12 on the opposite side
DESOXYN (methamphetamine hydrochloride tablets) is supplied as white tablets imprinted with the letters OV on one side and the number 12 on the opposite side, containing 5 mg methamphetamine hydrochloride in bottles of 100 (NDC 82983-418-10).
Recommended Storage: Store at 68°F to 77°F (20°C to 25°C). [see USP Controlled Room Temperature].
Dispense in a USP tight, light resistant container.
Distributed by: Ajenat Pharmaceuticals, LLC 203 N Marion St. Tampa, FL 33602, USA. Revised: Sep 2024
The following adverse reactions are discussed in greater detail in other sections of the labeling:
The following adverse reactions associated with the use of DESOXYN were identified in clinical trials or postmarketing reports. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Cardiovascular: Elevation of blood pressure, tachycardia and palpitation. Fatal cardiorespiratory arrest has been reported, mostly in the context of abuse/misuse
Central Nervous System: Psychotic episodes reported at recommended doses. Dizziness, dysphoria, overstimulation, euphoria, insomnia, tremor, restlessness and headache. Exacerbation of motor and verbal tics and Tourette’s syndrome
Gastrointestinal: Diarrhea, constipation, dryness of mouth, unpleasant taste, intestinal ischemia, and other gastrointestinal disturbances
Hypersensitivity: Urticaria
Endocrine: Impotence and changes in libido; frequent or prolonged erections
Musculoskeletal: Rhabdomyolysis
Metabolism and Nutrition Disorders: Suppression of growth has been reported with the longterm use of stimulants in pediatric patients
Skin and Subcutaneous Tissue Disorders: Alopecia
The following additional adverse reactions have been identified during post approval use of amphetamines:
Allergic: Rash, hypersensitivity reactions, including angioedema and anaphylaxis. Serious skin rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported.
Cardiovascular: Dyspnea, sudden death, myocardial infarction. There have been isolated reports of cardiomyopathy associated with chronic amphetamine use
Central Nervous System: dyskinesia, fatigue, aggression, anger, logorrhea, dermatillomania, and paresthesia (including formication)
Eye Disorders: Mydriasis
Vascular Disorders: Raynaud’s phenomenon
Table 1 presents clinically important drug interactions with DESOXYN.
Table 1: Clinically Important Drug Interactions with DESOXYN
| Monoamine Oxidase Inhibitors (MAOI) | |
| Clinical Impact: | MAOI antidepressants slow amphetamine metabolism, increasing amphetamines effect on the release of norepinephrine and other monoamines from adrenergic nerve endings causing headaches and other signs of hypertensive crisis. Toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results. |
| Intervention: | Concomitant use of DESOXYN with monoamine oxidase inhibitors (MAOIs) or within 14 days after discontinuing MAOI treatment is contraindicated [see CONTRAINDICATIONS]. |
| Serotonergic Drugs | |
| Clinical Impact: | The concomitant use of amphetamines, including DESOXYN, and serotonergic drugs increases the risk of serotonin syndrome. |
| Intervention: | Initiate DESOXYN with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during DESOXYN initiation or dosage increase. If serotonin syndrome occurs, discontinue DESOXYN and the concomitant serotonergic drug(s) [see WARNINGS AND PRECAUTIONS]. |
| Alkalinizing Agents | |
| Clinical Impact: | Alkalinizing agents may increase exposure to amphetamines and potentiate the action of amphetamine. |
| Intervention: | Avoid co-administration of DESOXYN and gastrointestinal and urinary alkalinizing agents. |
| Acidifying Agents | |
| Clinical Impact: | Acidifying agents lower blood levels and efficacy of amphetamines. |
| Intervention: | Increase dose of DESOXYN based on clinical response. |
| Tricyclic Antidepressants | |
| Clinical Impact: | May enhance the activity of tricyclic or sympathomimetic agents causing sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated. |
| Intervention: | Monitor frequently and adjust DESOXYN dose or use alternative therapy based on clinical response. |
| CYP2D6 Inhibitors | |
| Clinical Impact: | Concomitant use of DESOXYN and CYP2D6 inhibitors may increase the exposure of DESOXYN compared to the use of the drug alone, and increase the risk of serotonin syndrome. |
| Intervention: | Start with lower doses and monitor patients for signs and symptoms of serotonin syndrome particularly during DESOXYN initiation and after a dosage increase. If serotonin syndrome occurs, discontinue DESOXYN and the CYP2D6 inhibitor [see WARNINGS AND PRECAUTIONS]. |
| Gastric pH Modulators | |
| Clinical Impact: | Time to maximum concentration (Tmax) of amphetamine is decreased compared to when administered alone. |
| Intervention: | Monitor patients for changes in clinical effect and use alternative therapy based on clinical response. |
| Guanethidine | |
| Clinical Impact: | Methamphetamine may decrease the hypotensive effect of guanethidine. |
| Intervention: | Monitor patients and adjust therapy based on clinical response. |
Insulin requirements in diabetes mellitus may be altered in association with the use of methamphetamine and the concomitant dietary regimen.
Amphetamines can cause a significant elevation in plasma corticosteroid levels. This increase is greatest in the evening. Amphetamines may interfere with urinary steroid determinations.
DESOXYN contains methamphetamine hydrochloride, a Schedule II controlled substance.
DESOXYN has a high potential for abuse and misuse which can lead to the development of a substance use disorder, including addiction [see WARNINGS AND PRECAUTIONS]. DESOXYN can be diverted for non-medical use into illicit channels or distribution.
Abuse is the intentional non-therapeutic use of a drug, even once, to achieve a desired psychological or physiological effect. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a healthcare provider or for whom it was
not prescribed. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence.
Misuse and abuse of methamphetamine may cause increased heart rate, respiratory rate, or blood pressure; sweating; dilated pupils; hyperactivity; restlessness; insomnia; decreased appetite; loss of coordination; tremors; flushed skin; vomiting; and/or abdominal pain. Anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation have also been observed with CNS stimulants abuse and/or misuse. Misuse and abuse of CNS stimulants, including DESOXYN, can result in overdose and death [see OVERDOSE ], and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.
Physical Dependence
DESOXYN may produce physical dependence. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug.
Withdrawal signs and symptoms after abrupt discontinuation or dose reduction following prolonged use of CNS stimulants including DESOXYN include dysphoric mood; depression; fatigue; vivid, unpleasant dreams; insomnia or hypersomnia; increased appetite; and psychomotor retardation or agitation.
Tolerance
DESOXYN may produce tolerance. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose).
Included as part of the "PRECAUTIONS" Section
DESOXYN has a high potential for abuse and misuse. The use of DESOXYN exposes individuals to the risks of abuse and misuse, which can lead to the development of a substance use disorder, including addiction. DESOXYN can be diverted for non-medical use into illicit channels or distribution [see Drug Abuse And Dependence ]. Misuse and abuse of CNS stimulants, including DESOXYN, can result in overdose and death [see OVERDOSE ], and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.
Before prescribing DESOXYN, assess each patient’s risk for abuse, misuse, and addiction. Educate patients and their families about these risks and proper disposal of any unused drug. Advise patients to store DESOXYN in a safe place, preferably locked, and instruct patients to not give DESOXYN to anyone else. Throughout DESOXYN treatment, reassess each patient’s risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction.
Sudden death has been reported in patients with structural cardiac abnormalities and other serious cardiac disease who were treated with CNS stimulants at recommended ADHD dosage.
Avoid DESOXYN use in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmia, coronary artery disease, and other serious heart problems.
CNS stimulants cause an increase in blood pressure (mean increase about 2 to 4 mm Hg) and heart rate (mean increase about 3 to 6 bpm). Some patients may have larger increases.
Monitor all DESOXYN-treated patients for potential tachycardia and hypertension [see ADVERSE REACTIONS].
CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder.
CNS stimulants may induce a mixed or manic episode in patients with bipolar disorder. Prior to initiating DESOXYN treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or has a history of depressive symptoms or a family history of suicide, bipolar disorder, and depression).
CNS stimulants, at recommended doses, may cause psychotic or manic symptoms (e.g., hallucinations, delusional thinking, or mania) in patients without prior history of psychotic illness or mania. In a pooled analysis of multiple short-term, placebo-controlled studies of CNS stimulants, psychotic or manic symptoms occurred in 0.1% of CNS stimulant-treated patients compared to 0% in placebo-treated patients. If such symptoms occur, consider discontinuing DESOXYN.
CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients. Closely monitor growth (weight and height) in DESOXYN-treated pediatric patients treated with CNS stimulants.
Pediatric patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted.
CNS stimulants, including DESOXYN, used to treat ADHD are associated with peripheral vasculopathy, including Raynaud’s phenomenon. Signs and symptoms are usually intermittent and mild; however, very rare sequelae include digital ulceration and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynaud’s phenomenon, were observed in post-marketing reports at different times and at therapeutic doses in all age groups throughout the course of treatment. Signs and symptoms generally improve after reduction in dose or discontinuation of CNS stimulant.
Careful observation for digital changes is necessary during DESOXYN treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for DESOXYN-treated patients who develop signs or symptoms of peripheral vasculopathy.
DESOXYN may lower the convulsive threshold in patients with prior history of seizure, in patients with prior EEG abnormalities in the absence of seizures, and in patients without a history of seizures and no prior EEG evidence of seizures. In the presence of seizures, DESOXYN should be discontinued.
Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John’s Wort [see DRUG INTERACTIONS]. The coadministration with cytochrome P450 2D6 (CYP2D6) inhibitors may also increase the risk with increased exposure to DESOXYN. In these situations, consider an alternative nonserotonergic drug or an alternative drug that does not inhibit CYP2D6 [see DRUG INTERACTIONS].
Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea).
Concomitant use of DESOXYN with MAOI drugs is contraindicated [see CONTRAINDICATIONS].
Discontinue treatment with DESOXYN and any concomitant serotonergic agents immediately if the above symptoms occur, and initiate supportive symptomatic treatment. If concomitant use of DESOXYN with other serotonergic drugs or CYP2D6 inhibitors is clinically warranted, initiate DESOXYN with lower doses, monitor patients for the emergence of serotonin syndrome during drug initiation or titration, and inform patients of the increased risk for serotonin syndrome.
CNS stimulants, including amphetamine, have been associated with the onset or exacerbation of motor and verbal tics. Worsening of Tourette’s syndrome has also been reported [see ADVERSE REACTIONS].
Before initiating DESOXYN, assess the family history and clinically evaluate patients for tics or Tourette’s syndrome. Regularly monitor DESOXYN -treated patients for the emergence or worsening of tics or Tourette’s syndrome, and discontinue treatment if clinically appropriate.
Advise the patient to read the FDA-approved patient labeling (Medication Guide).
Educate patients and their families about the risks of abuse, misuse, and addiction of DESOXYN, which can lead to overdose and death, and proper disposal of any unused drug [see WARNINGS AND PRECAUTIONS, Drug Abuse And Dependence, OVERDOSE]. Advise patients to store DESOXYN in a safe place, preferably locked, and instruct patients to not give DESOXYN to anyone else.
Advise patients that there are potential risks to patients with serious cardiac disease, including sudden death with DESOXYN use. Instruct patients to contact a healthcare provider immediately if they develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease [see WARNINGS AND PRECAUTIONS].
Instruct patients that DESOXYN can cause elevations of their blood pressure and pulse rate and they should be monitored for such effects [see WARNINGS AND PRECAUTIONS].
Advise patients that DESOXYN, at recommended doses, may cause psychotic or manic symptoms even in patients without prior history of psychotic symptoms or mania [see WARNINGS AND PRECAUTIONS].
Advise patients, family members, and caregivers that DESOXYN may cause slowing of growth including weight loss [see WARNINGS AND PRECAUTIONS].
Instruct patients beginning treatment with DESOXYN about the risk of peripheral vasculopathy, including Raynaud’s Phenomenon, and associated signs and symptoms: fingers or toes may feel numb, cool, painful, and/or may change color from pale, to blue, to red. Instruct patients to report to their physician any new numbness, pain, skin color change, or sensitivity to temperature in fingers or toes. Instruct patients to call their physician immediately with any signs of unexplained wounds appearing on fingers or toes while taking DESOXYN. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients [see WARNINGS AND PRECAUTIONS].
Caution patient that DESOXYN may lower the convulsive threshold. Advise patients to contact their healthcare provider immediately and to discontinue DESOXYN if a seizure occurs [see WARNINGS AND PRECAUTIONS].
Caution patients about the risk of serotonin syndrome with concomitant use of DESOXYN and other serotonergic drugs including SSRIs, SNRIs, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John’s Wort, and with drugs that impair metabolism of serotonin (in particular MAOIs, both those intended to treat psychiatric disorders and also others such as linezolid [see CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS and DRUG INTERACTIONS]. Advise patients to contact their healthcare provider or report to the emergency room if they experience signs or symptoms of serotonin syndrome.
Advise patients that motor and verbal tics and worsening of Tourette’s syndrome may occur during treatment with DESOXYN. Instruct patients to notify their healthcare provider if emergence of new tics or worsening of tics or Tourette’s syndrome occurs [see WARNINGS AND PRECAUTIONS].
Advise patients to notify their physicians if they are taking, or plan to take, any prescription or over-the-counter drugs because there is a potential for interactions [see DRUG INTERACTIONS].
Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to DESOXYN during pregnancy. Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during treatment with DESOXYN. Advise patients of the potential fetal effects from the use of DESOXYN during pregnancy [see Use In Specific Populations ].
Advise patients not to breastfeed if they are taking DESOXYN [see Use In Specific Populations].
Carcinogenicity, mutagenic, or genotoxic potential of methamphetamine has not been fully characterized.
There have been no adequate studies performed in animals at current standards to evaluate the effect of methamphetamine treatment on fertility. However, published studies in mice and rats exposed to repeated daily dosing of methamphetamine report irregular estrous cycling and decreased ovarian reserve in females, and decreased sperm density, motility, and percent of sperm with normal morphology in males. The clinical significance of these findings is not clear.
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ADHD medications, including DESOXYN, during pregnancy. Healthcare providers are encouraged to advise patients to register by contacting the National Pregnancy Registry for ADHD Medications at 1-866-961-2388 or visiting online at www.womensmentalhealth.org/research/pregnancyregistry/adhd-medications/.
Available data from epidemiologic studies and postmarketing reports on use of methamphetamine and amphetamine in pregnant women over decades of use have not identified a drug-associated risk of major birth defects or miscarriage. Neonates exposed to amphetamines in utero are at risk for withdrawal symptoms following delivery. Adverse pregnancy outcomes including premature delivery and low birth weight have been seen in infants born to mothers taking amphetamines during pregnancy (see Clinical Considerations).
In animals, administration of methamphetamine during organogenesis resulted in developmental toxicity, including neonatal death and fetal malformations, at doses equivalent to the maximum recommended human dose (MRHD) on a mg/m2 basis. Oral administration of methamphetamine to rats during pregnancy, pregnancy and lactation, or lactation resulted in developmental toxicity in the offspring, including, neonatal mortality and delayed development, at a maternal dose similar to the MRHD on a mg/m2 basis.
The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Fetal/Neonatal Adverse Reactions
Amphetamines, such as DESOXYN, cause vasoconstriction and thereby decrease placental perfusion. In addition, amphetamines can stimulate uterine contractions, increasing the risk of premature delivery. Infants born to mothers taking amphetamines during pregnancy have an increased risk of premature delivery and low birth weight.
Monitor infants born to mothers taking methamphetamine for symptoms of withdrawal such as feeding difficulties, irritability, agitation, and excessive drowsiness.
Animal Data
Based on published data, methamphetamine administration during the period of organogenesis caused malformations and pup mortality in mammals at doses equivalent to the maximum recommended human dose (MRHD) on a mg/m2 basis. Oral administration of methamphetamine (0, or 3.75 mg/kg) to pregnant rats during gestation, throughout gestation and lactation, or only during lactation resulted in an increase in neonatal pup mortality. Delayed somatic development (pinna unfolding and eye opening) and impairments in neurobehavioral development (righting reflex, incline plane test, and forelimb grip strength) were observed in the pups. The dose with adverse effects was equivalent to the MRHD of 25 mg on a mg/m2 basis.
Based on limited case reports in the published literature, methamphetamine and its active metabolite, amphetamine, are present in human milk. There are no reports of adverse effects on the breastfed infant. Long-term neurodevelopmental effects on infants from amphetamine exposure are unknown. It is possible that large doses of amphetamine might interfere with milk production, especially in women whose lactation is not well established. Because of the potential for serious adverse reactions in nursing infants, advise patients that breastfeeding is not recommended during treatment with DESOXYN.
The safety and effectiveness of DESOXYN for the treatment of ADHD have been established in pediatric patients aged 6 years and older.
The safety and effectiveness of DESOXYN have not been established in pediatric patients younger than 6 years old.
Growth should be monitored during treatment with stimulants, including DESOXYN. Pediatric patients who are not growing or gaining weight as expected may need to have their treatment interrupted [see WARNINGS AND PRECAUTIONS, ADVERSE REACTIONS].
Clinical studies of DESOXYN did not include sufficient numbers of subjects age 65 years and over to determine whether elderly subjects respond differently from younger subjects.
Overdose of CNS stimulants is characterized by the following sympathomimetic effects:
Consider the possibility of multiple drug ingestion. D-amphetamine is not dialyzable.
Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.
DESOXYN is contraindicated in patients with:
Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. The exact mode of therapeutic action in the treatment of ADHD is not known.
Amphetamines block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.
Methamphetamine is absorbed from the gastrointestinal tract.
Metabolism
The primary site of metabolism is in the liver by aromatic hydroxylation, N-dealkylation and deamination. At least seven metabolites have been identified in the urine. The biological half-life has been reported in the range of 4 to 5 hours.
Excretion
Excretion occurs primarily in the urine and is dependent on urine pH. Alkaline urine will significantly increase the drug half-life. Approximately 62% of an oral dose is eliminated in the urine within the first 24 hours with about one-third as intact drug and the remainder as metabolites.
Desoxyn®
(De-soks-in)
(methamphetamine hydrochloride tablets)
What is the most important information I should know about DESOXYN?
DESOXYN may cause serious side effects, including:
Your child’s healthcare provider should check your child carefully for heart problems before starting treatment with DESOXYN. Tell your child’s healthcare provider if your child has any heart problems, heart disease, or heart defects.
Call your child’s healthcare provider or go to the nearest hospital emergency room right away if your child has any signs of heart problems such as chest pain, shortness of breath, or fainting during treatment with DESOXYN.
Tell your child’s healthcare provider about any mental problems your child has, or about a family history of suicide, bipolar illness, or depression.
Call your child’s healthcare provider right away if your child has any new or worsening mental symptoms or problems during treatment with DESOXYN, especially hearing voices, seeing or believing things that are not real, or new manic symptoms.
What is DESOXYN?
DESOXYN is a central nervous system (CNS) stimulant prescription medicine used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children 6 years to 17 years of age. DESOXYN may help increase attention and decrease impulsiveness and hyperactivity in people with ADHD.
It is not known if DESOXYN is safe and effective in children under 6 years of age.
DESOXYN is a federally controlled substance (CII) because it contains methamphetamine that can be a target for people who abuse prescription medicines or street drugs. Keep DESOXYN in a safe place to protect it from theft. Never give your DESOXYN to anyone else because it may cause death or harm them. Selling or giving away DESOXYN may harm others and is against the law.
Do not take DESOXYN if your child is:
Before taking DESOXYN, tell your child’s healthcare provider about all your child’s medical conditions, including if your child:
Tell your child’s healthcare provider about all of the medicines that your child takes including prescription and over-the-counter medicines, vitamins, and herbal supplements.
DESOXYN and some medicines may interact with each other and cause serious side effects. Sometimes the doses of other medicines will need to be changed during treatment with DESOXYN. Your child’s healthcare provider will decide whether DESOXYN can be taken with other medicines.
Especially tell your child’s healthcare provider if your child takes:
Ask your child’s healthcare provider if you are not sure if your child takes any of these medicines. Know the medicines your child takes. Keep a list of your child’s medicines with you to show your child’s healthcare provider and pharmacist. Do not start any new medicine during treatment with DESOXYN without talking to your child’s healthcare provider first.
How should DESOXYN be taken?
If your child takes too much DESOXYN, call your child’s healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.
What are possible side effects of DESOXYN?
DESOXYN may cause serious side effects, including:
Tell your child’s healthcare provider if your child has numbness, pain, skin color change, or sensitivity to temperature in your fingers or toes or if your child has any signs of unexplained wounds appearing on fingers or toes during treatment with DESOXYN.
The most common side effects with DESOXYN include:
These are not all the possible side effects of DESOXYN.
Call your child’s healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store DESOXYN?
Keep DESOXYN and all medicines out of the reach of children.
General information about the safe and effective use of DESOXYN.
Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use DESOXYN for a condition for which it was not prescribed. Do not give DESOXYN to other people, even if they have the same symptoms that your child has. It may harm them and it is against the law.
You can ask your child’s pharmacist or healthcare provider for information about DESOXYN that is written for healthcare professionals.
What are the ingredients in DESOXYN?
Active Ingredient: methamphetamine hydrochloride
Inactive Ingredients: corn starch, lactose, sodium paraminobenzoate, stearic acid and talc
Distributed by: Ajenat Pharmaceuticals, LLC 203 N Marion St. Tampa, FL 33602, USA. Revised: September 2024
